NEW YORK – IsoPlexis said on Tuesday that it has signed an exclusive agreement with Medquest to distribute IsoPlexis' products in Singapore and Malaysia.
Financial terms of the agreement were not disclosed.
Based in Branford, Connecticut, IsoPlexis markets products for single-cell proteomics research, including the IsoLight System, an automated platform for comprehensive functional protein and metabolite profiling of single cells.
"Our IsoLight platform provides a wide range of applications across numerous disease areas and we are excited for our systems to generate impactful data at leading pharmaceutical and life science institutions in Singapore and Malaysia," IsoPlexis CEO Sean Mackay said in a statement.
In July, IsoPlexis announced an exclusive distribution agreement in China with Neoline Technology.
Last week, IsoPlexis said that Switzerland-based Lonza will use the IsoLight platform for functional quality analytics for cell therapy products produced on Lonza's automated cell manufacturing platform. Also in August, IsoPlexis said it is partnering with researchers at Columbia University to study immune response in COVID-19 patients.